Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Out of Specification Tisagenlecleucel in pALL, LBCL, and NHL
NCT04094311Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Nov 2019
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
A Phase 3 trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), non-Hodgkin lymphoma (NHL), sponsored by Novartis. Started Nov 2019; status: recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04094311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094311.